The U.S. Food and Drug Administration today approved Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian,…
[Read More …]
from Back Pain Relief, http://www.xbackpain.com/fda-approves-new-maintenance-therapy-for-recurrent-cancers/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.